Original Source(s)
Related Content
FDA approves first factor XIa stroke drug
In a 12,327-patient trial, asundexian cut recurrent ischemic stroke risk by 26% alongside antiplatelets.
by Mouj Hijazi
November 10, 2026
-
3 min
Is Pharma Building the Right Facilities for Future Biologics?
As biologics portfolios expand and average product volumes fall, Miriam Monge asks whether today’s major manufacturing investments offer the flexibility tomorrow’s market will require
by Miriam Monge
November 9, 2026
-
5 min
Redefining Private Practice in Laboratory Medicine
A reflection on the progress, pressures, and changing trends that might threaten the future of pathology
November 9, 2026
-
5 min
